A recent prospective cohort “ESPRESSO” study (H Khalili et al. Gastroenterol 2020; 158: 1574-83) from 1990-2017 examined the risk of incident inflammatory bowel disease (IBD) in subjects with microscopic colitis, n=13,957 (& each matched with 5 controls). ESPRESSO = Epidemiology Strengthened by histoPathology Reports in Sweden.
- In the microscopic colitis group, there were 323 incident cases of ulcerative colitis (UC) and 108 cases of Crohn’s disease (CD)
- Mean times to diagnosis were 3.2 years for UC and 3.3 years for CD
- Microscopic colitis was associated with an aHR of 12.6 for CD and 17.3 fo rUC
- The absolute excess risk compared to matched control over a 10-year period were 2.6% for UC and 0.9% for CD
My take: Individuals with microscopic colitis are at increased risk of developing UC and CD.
Related blog post/related article:
- #NASPGHAN19 Postgraduate Course (Part 5)
- Full text PDF: AGA Microscopic Colitis Guideline: GC Nguyen et al. Gastroenterol 2016; 150: 242-6. Technical review DS Pardi et al. Gastroenterol 2016; 150: 247-74. Patient guide: pg 275.
Pingback: How Many Biopsies Are Sufficient for Diagnosis of Microscopic Colitis? | gutsandgrowth
Pingback: Vedolizumab for Refractory Microscopic Colitis, Plus, Vedolizumab and Serious Infections | gutsandgrowth